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S200 Poster Session Iof 2-year survival. Summary data regarding histologic subtype,
stage, immune status, viral load at ASCT and conditioning regi-
men will also be presented.
Conclusion: ASCT for HIV(+) patients has a comparable response
and survival to the HIV(-) population for ASCT. Consideration of
ASCT as an earlier therapeutic option in HIV related lymphoma
should be investigated. Additional prospective trials are necessary
to determine optimal management of this population.115
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Introduction: PB CD34+ cells are routinely monitored to optimize
the timing and success of CD34+ stem cell collection after G-CSF6
chemotherapy mobilization in NHL patients (pts) undergoing auto-
HSCT.A threshold of#10PBCD34+cells/ml is oftenused topredict
poor mobilization and aid the decision of whether novel therapies
such as plerixafor should be included in the mobilization scheme.
This analysis evaluatedwhether a PB threshold#10 cells/ml is indeed
the most optimal threshold to predict mobilization failure.
Methods:This was a post-hoc analysis of pts with NHL (enrolled in
the phase 3 study 3101) mobilized with G-CSF alone (10 mg/kg SC
for up to 8 doses). PB CD34+ cells were measured on the morning of
Day 4,24H prior to apheresis. The proportion of pts collecting the
minimal ($2  106) or optimal ($5  106) CD34+ cell dose and
apheresis yields were evaluated in pts with PB CD34+ cells/ml #10
(PB #10) or .10 (PB .10).
Results: This analysis was restricted to patients randomized to re-
ceive G-CSF plus placebo. In the 3101 study, 142 pts were mobi-
lized with G-CSF alone; Day 4 PB CD34 cell counts were available
for 124 pts. 75/124 (60%) pts had PB #10 and 49/124 (40%) pts
had PB .10. The median CD34+ cell yield in 2 days was 0.97 
106 cells/kg in pts with PB #10 and 3.3  106 cells/kg in pts
with PB .10. The median CD34+ cell yield in 4 days was 1.31
 106 cells/kg in pts with PB #10 and 4.52  106 cells/kg in pts
with PB .10. Only 22.7% pts with PB #10 and 65.3% pts with
PB .10 collected the minimal cell dose of $2 x106 cells/kg in 2
days. If apheresis was continued for 4 days then 34.7% pts with
PB #10 and 79.6% pts with PB .10 were able to collect the min-
imal dose. Similarly, only 5.3% pts with PB #10 and 30.6% pts
with PB .10 collected the optimal cell dose of $5 x106 cells/kg
in 2 days. Continuing apheresis for 4 days allowed 10.7% patients
with PB #10 and 40.8% patients with PB .10 to collect the opti-
mal dose.
Conclusion:Collectively, these data demonstrate that if apheresis
was planned in pts with .10 PB CD34+ cells/ml, then 20.4% pts
would not collect the minimal cell dose ($2106) and 59.2% pts
would not collect the optimal cell dose ($5106) in 4 apheresis
days. Thus, a threshold of .10 PB CD34+ cells/ml does not en-
sure adequate stem cell collection in a significant proportion of
NHL patients mobilized with G-CSF alone. Higher PB
CD34+ thresholds should be evaluated to ensure effective HSC
collection in NHL pts proceeding to HSCT.
Mobilization Outcomes in G-CSF Mobilized Patients with PB
#10 or PB. 10Median (range) cumulative CD341 cells/
kg x 106 after 2 apheresis days0.97 (0.06 - 9.16) 3.30 (0.46 - 12.00)Median (range) cumulative CD341 cells/
kg x 106 after 4 apheresis days1.31 (0.06 - 10.58) 4.52 (0.46 - 15.00)% Pts achieving $2 x 106 CD341Cells/
Kg in 2 days22.7 65.3% Pts achieving $2 x 106 CD341Cells/
Kg in 4 days34.7 79.6% Pts achieving $5 x 106 CD341Cells/
Kg in 2 days5.3 30.6% Pts achieving $5 x 106 CD341Cells/
Kg in 4 days10.7 40.8116
ADDITION OF BORTEZEMIB TO HIGH DOSE MELPHALAN DOES NOT IM-
PROVE RESPONSE RATE OR PROGRESSION-FREE SURVIVAL
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Background: High dose melphalan remains the preparative regi-
men of choice for autologous hematopoietic stem cell transplan-
tation (auto HCT) in multiple myeloma (MM). Bortezomib is
an active agent in newly diagnosed or relapsed MM, and has syn-
ergistic activity with melphalan. We recently conducted two ran-
domized phase II trials in MM, one of which studied the safety
and efficacy of adding bortezomib to high-dose melphalan in
the preparative regimen for auto HCT. Here we report the re-
sponse rates, progression-free survival (PFS) and overall survival
(OS) between the melphalan-based preparative regimens with or
without bortezomib.
Methods: In the first randomized trial 48 patients received high-
dose Melphalan at 100 mg/m2 IV on days -4 and -3, and ascorbic
acid (AA) 1000 mg IV daily on days -9 to -3. Patients in arm 1
did not receive arsenic trioxide (ATO); patients in arm 2 received
ATO 0.15 mg/kg IV from days -9 to -3; patients in arm 3 re-
ceived ATO at 0.25 mg/kg from days -9 to -3. In the second ran-
domized trial 60 patients were enrolled and 58 received an auto
HCT with a preparative regimen of melphalan 100 mg/m2 IV on
days -4 and -3, AA 1000 mg/day IV on days -9 to -3 and ATO
0.25 mg/kg IV on days -9 to -3. Patients in the second trial were
randomized to 3 arms; no bortezomib (arm 1), bortezomib 1 mg/
m2 on days -9, -6 and -3 (arm 2), and bortezomib 1.5 mg/m2 on
days -9, -6 and -3 (arm 3).
Results: A total of 106 patients received an auto HCT in these 2
trials. Of 106 patients, 39 received a preparative regimen with
bortezomib (Group A) and 67 without bortezomib (Group B). Pa-
tient characteristics and outcome are summarized in Table 1. Pa-
tients in group B (without bortezomib) were slightly older, had
a longer interval between diagnosis and auto HCT and 21%
had a prior auto HCT (vs. 2% in group A). Complete + very
good partial response rates (CR + VGPR) in groups A and B
were similar (31% vs. 31%). Median PFS and OS in group A
vs. B were 14 vs. 23 months (p5 0.08) and 80 vs. 82 months
(p5 0.17), respectively.
Conclusions: In this analysis of 106 patients, adding bortezomib to
a HD melphalan preparative regimen did not improve the response
rate, PFS or OS.
Patient Characteristics and Outcomes
Group A Group B
(Bortezomib) (No Bortezomib)Number of patients 39 67
Median age 59 55
Abnormal cytogenetics 13 11
Relapsed disease 10 25
Prior auto HCT 1 14
Months from diagnosis to auto HCT 9 14
Median CD34 dose 106/kg 3.9 4.56
Median days to engraftment 10 10
Grade 3-4 adverse effects 12 20
CR 7 (18%) 16 (24%)(Continued )
